The upregulation of ATG9B-4 leads to reduced ARNTL levels, which in turn results in increased CDK5 expression, promoting the malignant characteristics of liver cancer cells, suggesting that targeting the ATG9B-4/ARNTL/CDK5 signaling pathway may provide new therapeutic strategies for managing liver cancer. This evidence concerns the gene CDK5 and liver cancer.